This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Our Compounds

Boehringer Ingelheim is taking on cancer through a dedicated commitment to delivering first-in-class cancer cell-directed therapies, innovative immuno-oncology strategies and smart combination approaches.

Filter by:
Compound and target LATEST DEVELOPMENT PHASE
Phase I Phase II Phase III Approved
Cancer cell-directed and immuno-oncology therapies

STING agonist (in preparation)

TRAILR2/CDH17 antibody (in preparation)

Combination Approaches

STING agonist (in preparation) + PD-1 inhibitor (BI 75091)

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information..

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here.

 

Xentuzumab, BI 836858, BI 836880, BI 894999, BI 754091, BI754111, BI 891065, BI 907828, BI 905677, BI 765063, BI 1361849, SOS1::KRAS inhibitor, STING agonist and TRAILR2/CDH17 antibody are investigational compounds and have not been approved. Their safety and efficacy have not been established.

 

Ang2, angiopoietin 2; BET, bromodomain and extra terminal motif; CD, cluster of differentiation; CDH17, cell anchor cadherin 17; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; ErbB, epidermal growth factor receptor tyrosine kinase family receptor; FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2; IGF, insulin-like growth factor; KRAS, Kirsten rat sarcoma; LAG-3, lymphocyte activation gene 3 protein; LRP5/6, lipoprotein receptor-related protein 5/6; MDM2, murine double minute 2 protein; mRNA, messenger ribonucleic acid; NSCLC: non-small-cell lung carcinoma; PD-1, programmed cell death protein-1; PDGFR, platelet-derived growth factor receptor; SIRPα, signal-regulatory protein alpha; SMAC, second mitochondria-derived activator of caspase; SOS1, Son of sevenless homolog 1; STING, small molecule agonist of the stimulator of interferon genes; TRAILR2, tumour necrosis factor-related apoptosis-inducing ligand receptor 2; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

 

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: October 2019

References

1

Prescribing Information: GIOTRIF®. https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf (Accessed: October 2019).

2

Prescribing Information: VARGATEF®. https://www.ema.europa.eu/en/documents/product-information/vargatef-epar-product-information_en.pdf (Accessed: October 2019).

3

ClinicalTrials.gov. NCT03099174. https://clinicaltrials.gov/ct2/show/NCT03099174 (Accessed: October 2019).

4

ClinicalTrials.gov. NCT02123823. https://clinicaltrials.gov/ct2/show/NCT02123823 (Accessed: October 2019).

5

ClinicalTrials.gov. NCT03659136. https://clinicaltrials.gov/ct2/show/NCT03659136 (Accessed: October 2019).

6

ClinicalTrials.gov. NCT03207191. https://clinicaltrials.gov/ct2/show/NCT03207191 (Accessed: October 2019).

7

ClinicalTrials.gov. NCT02632721. https://clinicaltrials.gov/ct2/show/NCT02632721 (Accessed: October 2019).

8

ClinicalTrials.gov. NCT03013998. https://clinicaltrials.gov/ct2/show/NCT03013998 (Accessed: October 2019).

9

ClinicalTrials.gov. NCT03468426. https://clinicaltrials.gov/ct2/show/NCT03468426 (Accessed: October 2019).

10

ClinicalTrials.gov. NCT02952248. https://clinicaltrials.gov/ct2/show/NCT02952248 (Accessed: October 2019).

11

ClinicalTrials.gov. NCT03156114. https://clinicaltrials.gov/ct2/show/NCT03156114 (Accessed: October 2019).

12

ClinicalTrials.gov. NCT03780725. https://clinicaltrials.gov/ct2/show/NCT03780725 (Accessed: October 2019).

13

ClinicalTrials.gov. NCT03433898. https://clinicaltrials.gov/ct2/show/NCT03433898 (Accessed: October 2019).

14

ClinicalTrials.gov. NCT03166631. https://clinicaltrials.gov/ct2/show/NCT03166631 (Accessed: October 2019).

15

ClinicalTrials.gov. NCT03697304. https://clinicaltrials.gov/ct2/show/NCT03697304 (Accessed: October 2019).

16

ClinicalTrials.gov. NCT02674152. https://clinicaltrials.gov/ct2/show/NCT02674152 (Accessed: October 2019).

17

ClinicalTrials.gov. NCT02689505. https://clinicaltrials.gov/ct2/show/NCT02689505 (Accessed: October 2019).

18

ClinicalTrials.gov. NCT02516553. https://clinicaltrials.gov/ct2/show/NCT02516553 (Accessed: October 2019).

19

ClinicalTrials.gov. NCT03449381. https://clinicaltrials.gov/ct2/show/NCT03449381 (Accessed: October 2019).

20

ClinicalTrials.gov. NCT03604445. https://clinicaltrials.gov/ct2/show/NCT03604445 (Accessed: October 2019).

21

ClinicalTrials.gov. NCT04111458. https://clinicaltrials.gov/ct2/show/NCT04111458 (Accessed: October 2019).

22

ClinicalTrials.gov. NCT03164772. https://clinicaltrials.gov/ct2/show/NCT03164772 (Accessed: October 2019).

23

Boehringer Ingelheim. Data on file.

24

Boehringer Ingelheim. Data on file.